Further investigation is warranted to explore the use of novel drugs and methods targeting miR-506-3p expression and test the use of HPIs in NSCLC with EGFR mutation resistant to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.